Register

Registration

Note : After Answered of Questionnaires / Survey Please Close it.
.

Metropolis Healthcare Ltd . Large Cap

BSE: 542650 | NSE: METROPOLIS
Healthcare
Live
20/04/2021 4:00:00 PM
2471.75 -18.65   (-0.75%)
BSE: price shown with 5 mins delayed.
Prev. Close 2490.40
Open Price 2508.00
Volume Traded 10213.00

Fundamentals

Year on Year Growth Rate (%)

Ajusted EPS Sales Adjusted Net Profit

Latest Financials

Standalone Consolidated
TTM EPS (Rs) 28.07 27.84
TTM Sales (Rs. Cr.) 740.92 913.23
BVPS (Rs.) 115.53 119.73
Reserves (Rs. Cr.) 580.33 601.8
P/BV 21.14 20.40
PE 87.01 87.73348
From the Market
52 Week High / Low (Rs) 2605/1150
Volume Traded 10213
Market Cap (Rs. Cr.) 12485.28
Equity (Rs. Cr.) 10.2233626
Face Value (Rs) 2
Industry PE 0

Quarterly Results

Quarterly Growth Rate (%)

Ajusted EPS Sales Net Profit Margin

Peers Data

Name Current Price(Rs) Market Cap. (Rs. cr.) Net Profit(Rs. cr.) Sales Growth(%)
Shree Pacetronix Ltd 0 4.17 0.28 -37.94
Medinova Diagnostic Services Ltd 26.35 26.3 0 64.36
Transgene Biotek Ltd 5.09 38.57 -10.96 0.00
Fortis Malar Hospitals Ltd 60.35 113.11 -9.06 -55.83
Poly Medicure Ltd 888.5 8518.99 92.38 -15.68
Metropolis Healthcare Ltd 2442.5 12485.28 112.05 -13.16
Fortis Healthcare Ltd 208 15703.13 513.33 -63.85
Max Healthcare Institute Ltd 235.2 22719.03 27.88 1081.20
Laurus Labs Ltd 443.4 23792.95 267.05 20.47
Dr Lal Pathlabs Ltd 2903.2 24196.68 223.18 -14.70
Apollo Hospitals Enterprise Ltd 3272.85 47058.56 470.3 -31.15

Technical

Sector

23387.09 280.75   (1.22%)

Index

47705.80 -243.62   (-0.51%)
9 Days Avg
Span A Span B 52 Week TenKan-Sen Kijun-Sen ChiKou-Sen
9 Days Avg

Score

Kindly subscribe to get access

Research Analytical

Kindly subscribe to get access

News

2021/04/15 11:11

Metropolis Healthcare announces delay in acquisition of Hitech Diagnostic

Metropolis Healthcare had previously announced that the indicative period for the completion of acquisition of Dr. Ganesan's Hitech Diagnostic Centre (Hitech) would be three months (3 months) from 17 January 2021. However, due to the urrent situation of COVID-19 pandemic as mutually agreed between both the parties, the aforementioned acquisition would be closed and completed within next 45 days.

Powered by Capital Market - Live News

About Company

Dr. Sushil Kanubhai Shah, one of the Promoters, commenced pathology business in January 1980 as a partnership firm in the name of Dr. V. K. Desai's Hospital, having Dr. Kanubhai M. Shah, Dr. Sushil Kanubhai Shah and Dr. Vasant Kalyandas Desai as partners. The partnership was continued by Dr. Sushil Kanubhai Shah, Dr. Kanubhai M. Shah and Dr. Duru Sushil Shah from September 30, 1981 onwards. In June 1989, upon death of Dr. Kanubhai M. Shah, the partnership was continued by Dr. Sushil Kanubhai Shah and Dr. Duru Sushil Shah. Prior to March 18, 1995, Dr. Sushil Kanubhai Shah was also carrying on a business of radioimmunoassay and pathology laboratory on a sole proprietorship basis. On March 20, 1995, the said sole proprietorship business was converted into a partnership with Dr. Sushil Kanubhai Shah, Dr. Duru Sushil Shah and Aparna S. Shah (Rajadhyaksha) as partners, in the name and style of Metropolis Lab. In January 1998, Ameera Sushil Shah was inducted as an additional partner in Metropolis Lab. With effect from February 1, 2002, the business of Metropolis Lab was transferred to Dr. V. K. Desai's Hospital as a going concern. In May 2002, Dr. G. S. K. Velu and Subbulakshmi K. Velu were admitted as partners in Dr. V. K. Desai Hospitals. The name of Dr. V. K. Desai's Hospital was changed to Metropolis Health Services in November 2002. Further, in April 2003, Ameera Sushil Shah, Jaswanti Kanubhai Shah, Sadacharan Gomanthybabu and Gomathybabu Gomathy were admitted as partners in Metropolis Health Services. In July 2003, Metropolis Health Services was converted into a private limited company as Metropolis Health Services (India) Private Limited ('MHSIPL'). The name of MHSIPL was changed to Metropolis Health Services (India) Limited ('MHSIL') pursuant to a Fresh Certificate of Incorporation Consequent upon Change of Name on Conversion to Public Limited Company' on March 1, 2006. In January 2009, MHSIL amalgamated with Pathnet India Private Limited, which was a wholly owned subsidiary of MHSIL. Pathnet India Private Limited was incorporated at New Delhi as a private limited company on November 10, 2000. The name of the Company was changed to Pathnet India Limited pursuant to a Fresh Certificate of Incorporation Consequent upon Change of Name on Conversion to Public Limited Company' on July 1, 2009. The name of the Company was changed to Metropolis Healthcare Limited pursuant to a Fresh Certificate of Incorporation Consequent upon Change of Name' granted by RoC on September 23, 2009. Metropolis Healthcare is one of the leading diagnostics companies in India. It has widespread presence across 19 states in India with leadership position in west and south India. Through its widespread operational network, it offers a comprehensive range of clinical laboratory tests and profiles, which are used for prediction, early detection, diagnostic screening, confirmation and/or monitoring of the disease. It also offers analytical and support services to clinical research organizations for their clinical research projects.The Company conducts its operations through their laboratory and service network. It has implemented a hub and spoke' model for quick and efficient delivery of services through their widespread laboratory and service network, which covers 197 cities in India. As of December 31, 2018, its laboratory network consists of 115 clinical laboratories, comprising (i) a global reference laboratory ('GRL') located in Mumbai, which is the main hub' and equipped to conduct majority of the tests offered by them; (ii) 14 regional reference laboratories ('RRLs') (out of which four are located outside India), which are equipped to conduct routine, semi-specialized and few specialized tests; (iii) 56 satellite laboratories (out of which one is located outside India), which are equipped to conduct routine and semi-specialized tests; and (iv) 44 express laboratories (out of which five are located outside India), which are equipped to conduct routine tests. Metropolis Healthcare has been awarded the tender by the National Aids Control Organization ('NACO') to collect specimens from 525 government-owned antiretroviral therapy (ART) centers and conduct HIV-1-Viral load tests. It also offers analytical services and support services such as logistics and electronic data interchange ('EDI') to contract research organizations for their clinical research projects. Outside India, it has laboratory operations in Ghana, Kenya, Zambia, Mauritius and Sri Lanka. In addition, it has also entered into agreements with third parties for collection and processing of specimens in Nepal, Nigeria, UAE and Oman. Metropolis' brand is recognized for delivering quality diagnostic and related healthcare tests and services. For instance, it received 'excellence in customer service and delivery' award from Biotrains in 2018, and also received special jury mention for 'service excellence (diagnostic center)' by FICCI at the Healthcare Excellence Awards 2018. In addition, its health campaign was recognized as 'best in health and fitness' in the Digital Campaign Awards 2018 by LH Insights.Metropolis Healthcare Ltd. came out with an Initial Public Offering (IPO) of 13,685,095 equity shares of Face Value of Rs 2/- each of the company for cash at a price of Rs 880 per equity share aggregating Rs 1204.29 Crores, consisting of an offer for sale of 6,272,335 equity shares by Dr. Sushil Kanubhai Shah (the promoter selling shareholder) aggregating to 551.97 Crores and 7,412,760 equity shares by Ca Lotus Investments (the investor selling shareholder) aggregating 652.32 Crores. The face value of equity shares is Rs 2/-each. The IPO was priced at Rs 880 per equity share.